However, E-cadherin suppression has also been reported to enhance CRC chemosensitivity to irinotecan and oxaliplatin in HT29 and SW620 cell lines, revealing the complexity of E-cadherin's role in cancer therapy (Skarkova et al., 2021). The gene discussed is CDH1; the disease is cancer.